{"id":"metformin-and-roflumilast","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Gastrointestinal disturbance (metformin)"},{"rate":"15-25","effect":"Nausea (roflumilast)"},{"rate":"10-15","effect":"Diarrhea (metformin)"},{"rate":"10-15","effect":"Headache (roflumilast)"},{"rate":"5-10","effect":"Weight loss (roflumilast)"},{"rate":"<1","effect":"Lactic acidosis (metformin, rare)"}]},"_chembl":{"chemblId":"CHEMBL193240","moleculeType":"Small molecule","molecularWeight":"403.21"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metformin decreases hepatic glucose production and improves peripheral insulin sensitivity, primarily used in type 2 diabetes. Roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor that increases intracellular cAMP levels in inflammatory cells, reducing the production of pro-inflammatory mediators. The combination targets both metabolic and inflammatory pathways, potentially beneficial in patients with concurrent diabetes and chronic obstructive pulmonary disease (COPD).","oneSentence":"This combination uses metformin to improve insulin sensitivity and glucose metabolism while roflumilast reduces airway inflammation by inhibiting phosphodiesterase-4.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:54:33.694Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus with concurrent COPD (investigational combination)"}]},"trialDetails":[{"nctId":"NCT05369793","phase":"PHASE3","title":"Clinical Study Evaluating the Safety and Efficacy of Roflumilast in Type 2 Diabetic Patients With Diabetic Neuropathy","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-08-01","conditions":"Type 2 Diabetes (Adult Onset), Diabetic Neuropathies","enrollment":60},{"nctId":"NCT01664624","phase":"PHASE1","title":"Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-07","conditions":"Type 2 Diabetes","enrollment":40},{"nctId":"NCT02187250","phase":"PHASE4","title":"PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2014-03","conditions":"PCOS, Obesity","enrollment":45},{"nctId":"NCT02037672","phase":"PHASE4","title":"PDE-4 Inhibitor Roflumilast and Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2013-09","conditions":"PCOS, Obesity","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Glucophage tablets and Daxas 500 micrograms film-coated tablets"],"phase":"marketed","status":"active","brandName":"metformin and roflumilast","genericName":"metformin and roflumilast","companyName":"University Medical Centre Ljubljana","companyId":"university-medical-centre-ljubljana","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses metformin to improve insulin sensitivity and glucose metabolism while roflumilast reduces airway inflammation by inhibiting phosphodiesterase-4. Used for Type 2 diabetes mellitus with concurrent COPD (investigational combination).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}